Literature DB >> 31385753

Imaging of Precision Therapy for Lung Cancer: Current State of the Art.

Hyesun Park1, Lynette M Sholl1, Hiroto Hatabu1, Mark M Awad1, Mizuki Nishino1.   

Abstract

Advances in characterization of molecular and genomic abnormalities specific to lung cancer have made precision therapy the current standard of care for lung cancer treatment. This article will provide a cutting-edge review of imaging of lung cancer in the current era of precision medicine. The focus of the article includes (a) an update on the recent advances in precision therapy for non-small cell lung cancer and their implications on imaging; (b) molecular and genomic biomarkers and pitfalls of image interpretations for lung cancer precision therapy; and (c) review of the current approaches and future directions of precision imaging for lung cancer, emphasizing emerging observations in longitudinal tumor kinetics, radiomics, and molecular and functional imaging. The article is designed to help radiologists to remain up to date in the rapidly evolving world of lung cancer therapy and serve as key members of multidisciplinary teams caring for these patients. © RSNA, 2019.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31385753      PMCID: PMC6776234          DOI: 10.1148/radiol.2019190173

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  123 in total

Review 1.  Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.

Authors:  Mizuki Nishino; Sree H Tirumani; Nikhil H Ramaiya; F Stephen Hodi
Journal:  Eur J Radiol       Date:  2015-03-23       Impact factor: 3.528

Review 2.  Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.

Authors:  D Westover; J Zugazagoitia; B C Cho; C M Lovly; L Paz-Ares
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

3.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

4.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

5.  Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.

Authors:  Mizuki Nishino; Suzanne E Dahlberg; Linnea E Fulton; Subba R Digumarthy; Hiroto Hatabu; Bruce E Johnson; Lecia V Sequist
Journal:  Acad Radiol       Date:  2016-01-08       Impact factor: 3.173

6.  Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.

Authors:  Mizuki Nishino; Suzanne E Dahlberg; Stephanie Cardarella; David M Jackman; Michael S Rabin; Nikhil H Ramaiya; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson
Journal:  Cancer       Date:  2013-08-06       Impact factor: 6.860

7.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

8.  Lung tumor growth: assessment with CT--comparison of diameter and cross-sectional area with volume measurements.

Authors:  S Gregory Jennings; Helen T Winer-Muram; Robert D Tarver; Mark O Farber
Journal:  Radiology       Date:  2004-06       Impact factor: 11.105

9.  Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.

Authors:  Ji Hyun Lee; Ho Yun Lee; Myung-Ju Ahn; Keunchil Park; Jin Seok Ahn; Jong-Mu Sun; Kyung Soo Lee
Journal:  Cancer Imaging       Date:  2016-03-16       Impact factor: 3.909

10.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245

View more
  6 in total

Review 1.  The application of artificial intelligence and radiomics in lung cancer.

Authors:  Yaojie Zhou; Xiuyuan Xu; Lujia Song; Chengdi Wang; Jixiang Guo; Zhang Yi; Weimin Li
Journal:  Precis Clin Med       Date:  2020-08-24

2.  Prediction Model for Tumor Volume Nadir in EGFR-mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors.

Authors:  Mizuki Nishino; Junwei Lu; Takuya Hino; Natalie I Vokes; Pasi A Jänne; Hiroto Hatabu; Bruce E Johnson
Journal:  J Thorac Imaging       Date:  2021-09-15       Impact factor: 3.000

3.  [Research Progress of Cancer-associated Fibroblasts in Lung Cancer].

Authors:  Chongbiao Huang; Jie Xu; Zengxun Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-04-20

4.  A CT-based nomogram for differentiating invasive fungal disease of the lung from bacterial pneumonia.

Authors:  Lian Li; Wei Chen; Meilin Gong; Jingmei Xu; Kang Li; Ke Li; Yuwei Xia; Yang Jing; Jiafei Chen; Jing Li; Jing Yang; Mingshan Du; Wenjing Hou; Yuan Ou
Journal:  BMC Med Imaging       Date:  2022-10-03       Impact factor: 2.795

5.  Radiomics nomogram for the prediction of 2019 novel coronavirus pneumonia caused by SARS-CoV-2.

Authors:  Xu Fang; Xiao Li; Yun Bian; Xiang Ji; Jianping Lu
Journal:  Eur Radiol       Date:  2020-07-03       Impact factor: 7.034

6.  Correction for Magnetic Field Inhomogeneities and Normalization of Voxel Values Are Needed to Better Reveal the Potential of MR Radiomic Features in Lung Cancer.

Authors:  Maxime Lacroix; Frédérique Frouin; Anne-Sophie Dirand; Christophe Nioche; Fanny Orlhac; Jean-François Bernaudin; Pierre-Yves Brillet; Irène Buvat
Journal:  Front Oncol       Date:  2020-01-31       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.